ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors
D Timmerman, F Planchamp, T Bourne… - International Journal of …, 2021 - ijgc.bmj.com
The European Society of Gynaecological Oncology (ESGO), the International Society of
Ultrasound in Obstetrics and Gynecology (ISUOG), the International Ovarian Tumour …
Ultrasound in Obstetrics and Gynecology (ISUOG), the International Ovarian Tumour …
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup
I Vergote, A Gonzalez-Martin, D Lorusso… - The Lancet …, 2022 - thelancet.com
Summary The Gynecologic Cancer InterGroup (GCIG) sixth Ovarian Cancer Conference on
Clinical Research was held virtually in October, 2021, following published consensus …
Clinical Research was held virtually in October, 2021, following published consensus …
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
N Concin, X Matias-Guiu, I Vergote, D Cibula… - International Journal of …, 2021 - ijgc.bmj.com
A European consensus conference on endometrial carcinoma was held in 2014 to produce
multi-disciplinary evidence-based guidelines on selected questions. Given the large body of …
multi-disciplinary evidence-based guidelines on selected questions. Given the large body of …
Uterine serous carcinoma
G Bogani, I Ray-Coquard, N Concin, NYL Ngoi… - Gynecologic …, 2021 - Elsevier
Serous endometrial cancer represents a relative rare entity accounting for about 10% of all
diagnosed endometrial cancer, but it is responsible for 40% of endometrial cancer-related …
diagnosed endometrial cancer, but it is responsible for 40% of endometrial cancer-related …
FIGO staging of endometrial cancer: 2023
JS Berek, X Matias‐Guiu, C Creutzberg… - … of Gynecology & …, 2023 - Wiley Online Library
Introduction Many advances in the understanding of the pathologic and molecular features
of endometrial cancer have occurred since the FIGO staging was last updated in 2009 …
of endometrial cancer have occurred since the FIGO staging was last updated in 2009 …
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label …
RL Coleman, D Lorusso, C Gennigens… - The Lancet …, 2021 - thelancet.com
Background Few effective second-line treatments exist for women with recurrent or
metastatic cervical cancer. Accordingly, we aimed to evaluate the efficacy and safety of …
metastatic cervical cancer. Accordingly, we aimed to evaluate the efficacy and safety of …
Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer
LA Hefler, N Concin, G Hofstetter, C Marth… - Clinical cancer …, 2008 - AACR
Purpose: To evaluate serum C-reactive protein (CRP) as prognostic variable in patients with
epithelial ovarian cancer (EOC). Experimental Design: In a multicenter study, preoperative …
epithelial ovarian cancer (EOC). Experimental Design: In a multicenter study, preoperative …
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial
JS De Bono, N Concin, DS Hong… - The lancet …, 2019 - thelancet.com
Background Tisotumab vedotin is a first-in-human antibody–drug conjugate directed against
tissue factor, which is expressed across multiple solid tumour types and is associated with …
tissue factor, which is expressed across multiple solid tumour types and is associated with …
Plasma fibrinogen levels and prognosis in patients with ovarian cancer: a multicenter study
S Polterauer, C Grimm, V Seebacher, N Concin… - The …, 2009 - academic.oup.com
Abstract Learning Objectives After completing this course, the reader will be able to:
Describe the role of fibrinogen in coagulation and the inflammatory response and explain its …
Describe the role of fibrinogen in coagulation and the inflammatory response and explain its …
Transdominant ΔTAp73 Isoforms Are Frequently Up-regulated in Ovarian Cancer. Evidence for Their Role as Epigenetic p53 Inhibitors in Vivo
N Concin, K Becker, N Slade, S Erster… - Cancer research, 2004 - AACR
Despite strong homology, the roles of TP53 and TP73 in tumorigenesis seem to be
fundamentally different. In contrast to TP53, tumor-associated overexpression of TP73 in …
fundamentally different. In contrast to TP53, tumor-associated overexpression of TP73 in …